Selux Diagnostics

Selux Diagnostics is developing a next-generation phenotypic (NGP) platform that promises to transform the treatment of infectious disease patients by significantly improving the speed and accuracy of targeted, personalized antibiotic therapy. Selux Diagnostics is revolutionizing patient care, saving lives, reducing hospital stays, and combating the growing epidemic of antibiotic resistance by decreasing the overuse of broad-spectrum drugs. Our rapid and accurate NGP antimicrobial susceptibility testing (AST) platform breaks the trade-off between speed and accuracy, enabling clinicians to provide personalized antimicrobial treatment within the first 24 hours, and for 99% of cases, within 5 hours.